CapVest Enters Exclusive Discussions With HLD on the Proposed Acquisition of TSG
10.2.2026 10:00:00 EET | Business Wire | Press release
CapVest Partners LLP (“CapVest”), a leading New York and London based investment firm, and HLD, the entrepreneurial European investment group, have entered exclusive discussions on CapVest’s proposed acquisition of a majority stake in TSG, a European leader in technical services for critical energy infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210375858/en/
Headquartered in Paris, France, TSG is a European leader in technical services for the energy industry with a pan-European footprint in over 30 countries and employing over 7,000 people. Originally focused on fuel station and private fleet energy infrastructure and systems, since HLD’s acquisition of the company in 2020 TSG has undergone significant transformation as a primary enabler of the energy transition, offering a diverse range of multi-energy technical services across Power (HV & LV electrical), Charge, Solar, Battery Energy Storage Systems (BESS), Biofuels and Gas & Biogas. Under HLD and management's leadership, annual revenues have grown to more than €1.4 billion with new energies accounting for approximately half of the revenue.
TSG’s current activities are focused on design, engineering and build, testing, equipment supply, maintenance and project management. As a result of these multi-energy capabilities, deep technical experience, and geographical coverage spanning 30 countries, TSG has established longstanding and trusted relationships with a diverse base of leading energy infrastructure operators, with many of these client relationships spanning several decades. TSG has achieved strong growth in recent years driven by positive medium- and long-term secular trends including the growing need for investment in critical energy infrastructure and the transition towards more sustainable multi-energy solutions.
As a leading private equity investor, CapVest is known for partnering with ambitious companies supplying essential goods and services and bringing deep sector expertise to its portfolio companies, making the firm ideally positioned to support TSG in its next phase of growth including accelerating organic growth and supporting further complementary acquisitions. Following completion of the proposed transaction, HLD and members of the management team will retain significant minority stakes in TSG, underscoring their confidence in the company’s future trajectory and commitment to supporting TSG’s ongoing growth.
Fred Raikes, Partner at CapVest, said: “We believe TSG is well positioned to accelerate international growth in the coming years, capitalising on its outstanding and highly skilled team, reputation for excellent quality of service and ongoing requirement of infrastructure operators to maintain, upgrade and provide more sustainable energy infrastructure and solutions. We look forward to working with Jean-Marc Bianchi and his team to build on their substantial successes to date and help unlock the very exciting growth opportunities ahead for TSG.”
Cédric Chateau, Partner and Chairman of the Investment Committee of HLD, said: “TSG has undergone a profound transformation and incredible acceleration during these past five years of HLD's shareholding alongside Jean-Marc Bianchi and his teams. The company has become a key player in the energy transition in Europe. The coming years are just as exciting for TSG, and we are delighted to extend this journey alongside the management and CapVest.”
Jean-Marc Bianchi, Chairman & CEO of TSG, said: “CapVest has an excellent reputation for working closely with management in transforming the size and scale of its portfolio companies and are an ideal next partner to work with us to realise our ambitious plans for the company. Their philosophy of undertaking significant investment in people, innovation and capabilities and focus on organic and acquisition led growth, strongly reflects our principles and plans and we very much look forward to working with them in the future. In the same vein, HLD have been excellent partners and we are very thankful for their contribution to all our successes to date and delighted they are still part of our journey.”
The transaction remains subject to the legal process of informing and consulting with relevant employee representative bodies, regulatory approvals in key jurisdictions where TSG operates, and other customary closing conditions.
The terms of the proposed transaction have not been disclosed.
Financial Advisors to CapVest were Perella Weinberg Partners and Rothschild & Co.
Financial Advisors to HLD were Amala Partners and Citi.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260210375858/en/
Contacts
For further information please contact:
On behalf of CapVest:
Ben Valdimarsson
Mob: +44 (0)7889 805930
bvaldimarsson@reputation-inc.com
On behalf of HLD:
DGM Conseil
Etienne Gautier
07 48 15 22 35
etienneg@dgm-conseil.fr
Charles-Etienne Lebatard
06 14 74 83 08
ce.lebatard@dgm-conseil.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 11:00:00 EET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 11:00:00 EET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 11:00:00 EET | Press release
The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying the foundations for the evolution of AI-supported oncological diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210610418/en/ On this
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 11:00:00 EET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 10:15:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living with NT1. NT1 is a chronic, rare neurological disease caused by a loss of orexin and characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). This results in a spectrum of physical, cognitive and psychosocial effects that can have a debilitating impact on many aspects of a person’s life, including work, education and social interactio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom